AdvaMed Launches National Search For New CEO As Ubl Plans Departure
This article was originally published in The Gray Sheet
AdvaMed CEO Steve Ubl is leaving the device trade association to take the helm of the Pharmaceutical Research and Manufacturers of America. Ubl has led AdvaMed for 10 years, raising the profile of the device industry among policymakers, fighting perception battles and, of course, opposing the device tax.
You may also be interested in...
Next AdvaMed Chief Is BIO Exec Scott Whitaker
Whitaker, appointed as the next CEO of AdvaMed, currently runs day-to-day operations at the Biotechnology Innovation Organization and has held high-level posts at HHS. Among his accomplishments, Whitaker led the legislative office at HHS when the first device user fee bill was passed in 2002.
PhRMA CEO: Ubl Pick Brings User Fee, Reimbursement Expertise
Steve Ubl has led AdvaMed for 10 years, raising profile of device industry on Capitol Hill and executing well-regarded public relations campaign of the kind the drug industry might need as it enters political maelstrom on pricing.
Device Industry Amps Up Efforts To Repeal Device Tax In Lame Duck Session
Industry groups flew in more than 50 CEOs to visit Capitol Hill, launched an ad campaign and released an impact report last week as part of a stepped-up effort to get Congress to repeal the impending medical device tax before it goes into effect Jan. 1.